Dr. Reddy's Laboratories Limited (NYSE:RDY - Free Report) - Equities research analysts at Zacks Research decreased their FY2026 EPS estimates for shares of Dr. Reddy's Laboratories in a research note issued on Tuesday, April 16th. Zacks Research analyst R. Department now forecasts that the company will post earnings per share of $4.11 for the year, down from their prior forecast of $4.12. The consensus estimate for Dr. Reddy's Laboratories' current full-year earnings is $3.96 per share.
Several other equities analysts have also weighed in on RDY. StockNews.com upgraded shares of Dr. Reddy's Laboratories from a "buy" rating to a "strong-buy" rating in a research report on Friday, April 5th. Jefferies Financial Group lowered shares of Dr. Reddy's Laboratories from a "buy" rating to an "underperform" rating in a research report on Thursday, January 11th. Finally, Barclays raised their price objective on shares of Dr. Reddy's Laboratories from $75.00 to $80.00 and gave the company an "overweight" rating in a research report on Monday, January 29th. One analyst has rated the stock with a sell rating, two have assigned a hold rating, one has issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of "Hold" and a consensus target price of $80.00.
Get Our Latest Research Report on RDY
Dr. Reddy's Laboratories Price Performance
RDY traded down $0.24 on Wednesday, reaching $71.37. The company had a trading volume of 141,889 shares, compared to its average volume of 195,413. The company has a fifty day moving average of $74.54 and a 200-day moving average of $70.17. The company has a market capitalization of $11.91 billion, a P/E ratio of 18.83, a PEG ratio of 1.77 and a beta of 0.58. The company has a current ratio of 2.55, a quick ratio of 1.90 and a debt-to-equity ratio of 0.02. Dr. Reddy's Laboratories has a one year low of $53.12 and a one year high of $77.72.
Dr. Reddy's Laboratories (NYSE:RDY - Get Free Report) last announced its earnings results on Wednesday, January 31st. The company reported $0.99 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.88 by $0.11. The firm had revenue of $867.00 million during the quarter, compared to analyst estimates of $827.81 million. Dr. Reddy's Laboratories had a net margin of 19.26% and a return on equity of 20.97%.
Institutional Inflows and Outflows
Several hedge funds and other institutional investors have recently made changes to their positions in the company. Sequoia Financial Advisors LLC boosted its holdings in shares of Dr. Reddy's Laboratories by 1.1% in the third quarter. Sequoia Financial Advisors LLC now owns 13,793 shares of the company's stock worth $922,000 after buying an additional 151 shares during the period. Envestnet Asset Management Inc. lifted its position in shares of Dr. Reddy's Laboratories by 1.5% in the third quarter. Envestnet Asset Management Inc. now owns 12,388 shares of the company's stock worth $648,000 after purchasing an additional 187 shares in the last quarter. Janney Montgomery Scott LLC lifted its position in shares of Dr. Reddy's Laboratories by 1.7% in the third quarter. Janney Montgomery Scott LLC now owns 12,550 shares of the company's stock worth $839,000 after purchasing an additional 214 shares in the last quarter. Ethic Inc. lifted its position in shares of Dr. Reddy's Laboratories by 6.2% in the fourth quarter. Ethic Inc. now owns 4,016 shares of the company's stock worth $279,000 after purchasing an additional 235 shares in the last quarter. Finally, Desjardins Global Asset Management Inc. lifted its position in shares of Dr. Reddy's Laboratories by 7.2% in the fourth quarter. Desjardins Global Asset Management Inc. now owns 3,786 shares of the company's stock worth $263,000 after purchasing an additional 255 shares in the last quarter. 14.02% of the stock is currently owned by institutional investors and hedge funds.
About Dr. Reddy's Laboratories
(
Get Free Report)
Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations.
See Also
Before you consider Dr. Reddy's Laboratories, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Dr. Reddy's Laboratories wasn't on the list.
While Dr. Reddy's Laboratories currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
